Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Azacitidine in MDS and AML
NCT00392353Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Incidence of toxicities at 1 month, Objective overall response proportion at 168 days and 1 more. Started Nov 2006; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00392353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392353.